Nomura Cuts JD HEALTH TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Nomura reported mixed 3Q results for JD HEALTH with revenue rising 17% YoY to RMB 20 billion and non-IFRS operating profit increasing 14% YoY to RMB 1.6 billion.
- Management lowered its full-year 2026 revenue growth guidance to mid-teens due to regulatory reviews and recalls, prompting Nomura to lower its 4Q revenue growth expectation to around 10%.…
Disclaimer

Nomura said in a research report that JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% 's third-quarter results were mixed. Revenue rose 17% YoY to RMB20 billion, 1% above the broker's forecast, mainly driven by a rebound in nutritional product sales. Non-IFRS operating profit increased 14% YoY to RMB1.6 billion, 2% below the broker's forecast, while operating margin edged down 0.2 ppts YoY to 7.9%, mainly due to higher marketing expenses.

Management lowered its full-year 2026 revenue growth guidance from high-teens to mid-teens, mainly due to one-off impacts from regulatory reviews and recalls involving certain key nutritional brands. The broker expects fourth-quarter revenue growth to slow to around 10%, but believes the third-quarter contraction in operating margin was temporary and that fourth-quarter non-IFRS operating profit may resume YoY expansion.

The broker lowered its 2026 and 2027 revenue forecasts for JD HEALTH by 2% and 3%, respectively, but raised its 2027 adjusted net profit forecast by 2%. It maintained the "Buy" rating and cut the TP from HKD60 to HKD51, equivalent to 10x adjusted P/E for 2027.(da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.